54.3 F
San Diego
Thursday, Mar 28, 2024
-Advertisement-

Cidara Therapeutics Reports Q1 Results

Cidara Therapeutics Inc. reported May 21 a net loss of $6.7 million for the first quarter of 2015, up from a net loss of $707,000 in the same quarter of last year.

The San Diego biotech reported research and development expenses for the first quarter of 2015 were $4.9 million, compared with $0.3 million for the first quarter of 2014. The company said the year-over-year increase is due to the expansion of the product candidate pipeline to include CD101 IV and CD101 topical as well as increased levels of pre-clinical activities for the Cloudbreak immunotherapy platform.

Cidara raised $69.3 million from an initial public offering in April, on top of a $42 million Series B round in February.

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-